• SungKyunKwan Univ. Master in Pharmacy
• Carnegie Mellon Univ, MBA (Finance)
• Lehman Brothers, Equity Research
(1-Yr Internship, New York)
• Bayer Schering Asia Pacific
- Business Development (In-licensing)
- Global Leader of Label Extension Program
in Hematology (BMT program)
• Bayer Korea
- Head of anticancer drug/rare disease business unit
• Novartis Korea
- Global Crew Leader of Market Access for Hepatis
B & C Program in Liver Disease
• Alvogen
- CDO (Korea) & Head of Strategic Planning
(Asia Pacific)
• Kolon PHARMA.
- Chief Development Officer
• iN Therapeutics (CEO)
• Carnegie Mellon Univ, MBA (Finance)
• Lehman Brothers, Equity Research
(1-Yr Internship, New York)
• Bayer Schering Asia Pacific
- Business Development (In-licensing)
- Global Leader of Label Extension Program
in Hematology (BMT program)
• Bayer Korea
- Head of anticancer drug/rare disease business unit
• Novartis Korea
- Global Crew Leader of Market Access for Hepatis
B & C Program in Liver Disease
• Alvogen
- CDO (Korea) & Head of Strategic Planning
(Asia Pacific)
• Kolon PHARMA.
- Chief Development Officer
• iN Therapeutics (CEO)
Speaking In
2:30 PM - 2:45 PM (EST)
Monday, February 6
IN Therapeutics(INT) is a spin-out subsidiary of Daewoong Pharma, one of the local leading pharma…
Winter Garden